AstraZeneca's Imfinzi fails bladder cancer trial — in patient population covered by FDA's 2017 accelerated approval
A post-approval commitment testing Imfinzi in a late-stage bladder cancer population has gone pear-shaped for AstraZeneca, as the checkpoint inhibitor failed to help patients live longer in an open-label pivotal study.
Back in 2017, the PD-L1 drug was granted accelerated approval by the FDA for patients with locally advanced or metastatic bladder cancer whose disease has persisted despite platinum-containing chemotherapy on the basis of Phase I/II data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.